You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

CLINICAL TRIALS PROFILE FOR DAROLUTAMIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Darolutamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02200614 ↗ Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer Completed Orion Corporation, Orion Pharma Phase 3 2014-09-12 The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
NCT02200614 ↗ Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer Completed Bayer Phase 3 2014-09-12 The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
NCT02799602 ↗ ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Active, not recruiting Orion Corporation, Orion Pharma Phase 3 2016-11-30 The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
NCT02799602 ↗ ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Active, not recruiting Bayer Phase 3 2016-11-30 The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Darolutamide

Condition Name

Condition Name for Darolutamide
Intervention Trials
Prostate Cancer 20
Metastatic Prostate Cancer 8
Prostatic Neoplasms 5
Prostate Adenocarcinoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Darolutamide
Intervention Trials
Prostatic Neoplasms 54
Adenocarcinoma 7
Hypersensitivity 6
Carcinoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Darolutamide

Trials by Country

Trials by Country for Darolutamide
Location Trials
United States 260
Japan 80
Brazil 55
Canada 55
Germany 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Darolutamide
Location Trials
California 15
New York 12
Michigan 12
Pennsylvania 11
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Darolutamide

Clinical Trial Phase

Clinical Trial Phase for Darolutamide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 16
Phase 2 28
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Darolutamide
Clinical Trial Phase Trials
Recruiting 29
Not yet recruiting 21
Active, not recruiting 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Darolutamide

Sponsor Name

Sponsor Name for Darolutamide
Sponsor Trials
Bayer 30
National Cancer Institute (NCI) 6
AstraZeneca 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Darolutamide
Sponsor Trials
Other 59
Industry 53
NIH 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.